241
Participants
Start Date
February 24, 2017
Primary Completion Date
April 24, 2024
Study Completion Date
April 24, 2024
LXH254
LXH254 will be supplied as tablet for oral use.
LTT462
LTT462 will be supplied as hard gelatin capsule for oral use.
Trametinib
Trametinib will be supplied as film-coated tablet for oral use
Ribociclib
Ribociclib will be supplied in tablets and hard gelatin capsules.
Novartis Investigative Site, Westmead
Novartis Investigative Site, Melbourne
Novartis Investigative Site, Leuven
Memorial Sloan Kettering Cancer Ctr ., New York
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Madrid
Novartis Investigative Site, Pamplona
Novartis Investigative Site, Verona
Sarah Cannon Research Institute Tennessee Oncology, Nashville
Novartis Investigative Site, Seville
Novartis Investigative Site, Essen
Novartis Investigative Site, Valencia
Novartis Investigative Site, Cologne
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Lyon
Novartis Investigative Site, Paris
Uni of TX MD Anderson Cancer Cntr, Houston
Novartis Investigative Site, Napoli
University of California San Diego ., San Diego
UCSF Medical Center, San Francisco
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Tel Aviv
Massachusetts General Hospital SC, Boston
Novartis Investigative Site, Dresden
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Stockholm
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY